The incidence of clinical apparent cerebral embolism in patients (pts) with atrial fibrillation (AF) who underwent transesophageal echocardiographical (TEE) guided cardioversion is approximately 1%. The incidence of clinically silent cerebral embolism has not been analysed yet. The aims of this prospective studies were (1) to evaluate the prognosis of cardioversion in pts with AF and (2) to assess the incidence of cerebral embolism with MR-imaging (MRI).
Background: Patients (pts) with atrial fibrillation (AF) and spontaneous echo contrast (SEC) have an increased stroke risk. The aims of this prospective study were (1) to evaluate the prognosis of pts with dense SEC and (2) to assess the incidence of cerebral embolism with MR-imaging (MRI) under continued oral anticoagulation therapy. Methods: The study group consisted of 64 pts with SEC and AF. 28 pts served as controls. All pts received oral anticoagulation therapy during the follow-up period (an INR > 2 was defined as effectively anticoagulated). To document the incidence of cerebral embolism all pts underwent the following examinations at admission and at 1, 3 and 12 months: transthoracic and transesophageal echocardiography, cranial MRI including diffusion-weighted MRI, assessment of the anticoagulation level and neurological assessment. Results: 2 pts had clinically silent cerebral embolism at the index examination. Two patients (3%) had cerebral embolism with neurological deficit during the follow-up period. Four (6%) pts died during the observation period due to stroke. Additionally, 6 (9%) pts had new appeared focal diffusion abnormalities in the MRI during the follow-up. 45 (70%) pts were effectively anticoagulated, 15 (23%) pts were anticoagulated inadequately during the 12 months. Pts with cerebral embolism had lower left atrial appendage peak empty velocities (0.22 ± 0.14 vs. 0.38 ± 0.21; p<0.01) and denser SEC (2.8 ± 1.1 vs. 1.6 ± 1.4; p<0.01) than pts without cerebral events. Conclusions: Pts with AF and SEC have an increased risk of cerebral embolism despite oral anticoagulation therapy. Low peak empty velocities of the left atrial appendage and dense SEC are echocardiographic predictors for a cerebral event.
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Cardioversion Background. Atrial fibrillation (AF) is the most common human arrhythmia with a prevalence in the elderly population of up to 15%. It results in breathlessness, palpitations and systemic embolisation due to a procoagulant state. Recent studies of AF have suggested that rate control with anticoagulation may have a superior outcome compared to rhythm control. The aim of this study was to assess the effect of D.C. cardioversion on markers of coagulation and platelet activity and endothelial function in patients with AF on warfarin therapy. Methods Sixty patients undergoing elective D.C cardioversion for non-valvular atrial fibrillation were recruited to the study. All patients were taking warfarin aiming for an INR of 2-3. D.C cardioversion was performed under general anaesthetic following our local protocol. Peripheral venous blood was sampled through a 16G needle prior to cardioversion and at 2,4,6 and 10 weeks post cardioversion provided they remained in sinus rhythm (SR). Warfarin was discontinued 6 weeks after cardioversion. The samples were assayed for INR, prothrombin fragment 1+2, d-dimer, beta thromboglobulin, and von Williebrand factor. Results. Nine patients failed to cardiovert to sinus rhythm, and 8 people withdrew from the study. Median age was 65 (39-77) years. Mean INR was 2.4±0.3. At 2 weeks, 20 patients remained in SR and 23 had reverted to AF. Compared to baseline, D.C. cardioversion produced no significant change in prothrombin fragment 1+2 (p=0.1), d-dimer (p=0.3), beta thromboglobulin (p=0.3), or von Williebrand factor (p=0.6). No significant change in coagulation or platelet activity was seen at 4 weeks (n=15) or 6 weeks (n=18), compared to baseline. At 10 weeks, once warfarin was discontinued, only prothrombin fragment 1+2 levels were higher than at baseline (p=0.009). Conclusion. Achieving rhythm control with D.C. cardioversion does not improve coagulation or platelet markers in patients with AF. This study may in part explain why rate control with anticoagulation seems superior to rhythm control in patients with AF.
1129-213 Which Patients With Atrial Fibrillation or Atrial Flutter Benefit From Electrical Cardioversion?
Ahmad A. Elesber, A. Gabriela Rosales, Joseph Maalouf, Nasser Ammash, David Hodge, Stephen C. Hammill, Paul A. Friedman, Mayo Clinic, Rochester, MN Background: Optimal management of new onset atrial fibrillation (Afib) or flutter (Aflu) is not known. We sought to determine the recurrence rate of atrial arrhythmia post electrical cardioversion (DCCV) of new onset Afib and Aflu. Methods: A cohort of 244 patients (pts) with documented Afib (119 with new onset Afib) and 79 pts with Aflu (52 with new onset Aflu) were followed after DCCV for recurrence. Post-surgical pts with Afib or Aflu were excluded. Cox proportional hazards models were used to construct multivariate models. Results: The mean age was 71.1±12.4 years with 69% being males, 30% had coronary artery disease, 19% had congestive heart failure and 68% had hypertension. The mean follow up was 159.5±171.2 days. Pts with recurrent Afib (57.6%) or recurrent Aflu (63%) were more likely to be on antiarrhythmic medications than pts with new onset Afib (19.3%) or new onset Aflu (3.9%), p<0.05. In a multivariate model, pts with a bigger right atrial size (p=0.02) or mitral valve disease (p<0.01) were more likely to have recurrence of atrial arrhythmia. Use of antiarrhythmic medications had no effect on recurrence. Pts with new onset Aflu were less likely to recur after DCCV than pts with new onset Afib or either recurrent Aflu or Afib, p<0.001 (see figure) . Conclusion: DCCV for pts with new onset Aflu is a reasonable strategy with 65% of pts maintaining sinus rhythm at 1.5 years of follow-up. Only 20% of pts with Afib or recurrent Aflu remained in sinus rhythm at 1.5 years of follow-up. 
